Podcasts about Eli Lilly

Cognitive health is the topic of the day on NP Pulse: The Voice of the Nurse Practitioner®, and joining the podcast is returning guest Shonda Phelon — an academic, nurse practitioner and expert in mental health. Phelon talks about opening the conversation around cognition decline early; the importance of encouraging active brains and bodies; and walks us through the latest updates in testing and cognitive assessment. This podcast is made possible by Eli Lilly & Co.

Lee Brown sees lots of potential in the weight loss drug space, noting Eli Lilly (LLY) and Novo Nordisk (NVO) as the two companies he expects to lead. He points to "incredible" discounts and expanded access to GLP-1s as indicators these companies will see wider moats for their products. Lee adds that the recent pharma tariffs from the Trump administration will benefit U.S.-based companies, but adds that tariffs will prove to be a long-term overhang. Tom White offers an example options trade for Eli Lilly.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels.   Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said.   “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.”   Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.   https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas.   The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/     XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay     XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition.   G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment.   The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes.   "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes.   The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting  it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems.   https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).   – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. ​This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November.   ​ https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/   XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. ,   The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say.   In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries."   The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours.   Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy.   At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy.   Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells.   Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially.   Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells.   “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release.   “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy   XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen Gamechanger-Deal, Wall-Street-Rekorde trotz Shutdown und das fulminante Börsendebüt von Fermi. Außerdem geht es um Pfizer, Merck, Eli Lilly, Novo Nordisk, Vertex, Regeneron, Thermo Fisher, Repligen, Danaher, Boston Scientific, Abbott, Intuitive Surgical, Bayer, Merck, Salzgitter, Thyssenkrupp, Bitcoin, Solana, Ether, Sartorius, Palantir Technologies, Thales, L3Harris Technologies, RTX, Kratos Defense & Security Solutions, AeroVironment, DroneShield, Elbit Systems, Electro Optic Systems, Saab AB, Hensoldt, Mercury Systems, QinetiQ, Chemring Group, Cohort, Exail Technologies, Rocket Lab, Iridium Communications, BlackSky Technology, Electro Optic Systems, Leidos Holdings, CACI International, Parsons, Telos Corp, Leidos, SAIC, QinetiQ, Parsons VanEck Space Innovators ETF (WKN: A3DP9J), Invesco Defence Innovation ETF (WKN: A40J95), Global X Defence Tech ETF (WKN: A40E7A), Droneshield, Palantir, Red Cat Holdings. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

When someone finishes a cancer treatment, it can feel like the end of the story. For many, it may just be the beginning–risk of recurrence looms, long-term medications (and their side effects) begin, and it’s hard to get your bearings. What do you really need to know?In this candid conversation, Katie sits down with Dr. Lillian Smyth, Senior Vice President and Global Development Head for Breast Cancer at Eli Lilly and Company, and LaShae Rolle, a breast cancer survivor, public health researcher, and powerlifter. Together, they explore what life after breast cancer treatment really looks like: from follow-up care and managing side effects to navigating fears about recurrence and finding strength in advocacy.This episode—created in partnership with Eli Lilly—is about more than medicine. It’s about empowerment: knowing your “normal,” asking the right questions, and embracing life following cancer treatment.See omnystudio.com/listener for privacy information.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über die großen Verschiebungen im 3. Quartal, Trumps wirren Deal mit Pfizer und Wolfspeed, die wie Phoenix aus der Asche steigen. Außerdem geht es um Applovin, Western Digital Corp, Warner Bros, Seagate Technologies, Intel, Tesla, Charter Communications, Trade Desk, Lululemon, FactSheet, Molina Healthcare, Gartner, Commerzbank, Deutsche Bank, BMW, Airbus, Fresenius, Bayer, Deutsche Börse, Symrise, Beiersdorf, Lithium America, Berkshire Hathaway, Occidental Petroleum, Nike, Adidas, Puma, Electronic Arts, MoonLake Immunotherapeutics, Insmed Incorporated, Madrigal Pharmaceuticals, Krystal Biotech, Mineralys Therapeutics, Vera Therapeutics, Summit Therapeutics, TripAdvisor, Zoom Communications, Unity Software, Workiva, Trimble, Take-Two Interactive Software, Avepoint, Groupon, Magnolia Oil, Kinetik Holdings, Kosmos Energy, Parsons Corporation, Hexcel Corporation, Science Applications International, Kratos Defense & Security Solutions, Scout24, Brenntag, Hugo Boss, Nordex, Temenos, Avolta, Burberry, Remy Cointreau, Whitbread, Reckitt Benckiser, Amadeus IT Group, Moncler, Signify, Iveco Group, EDP Renovaveis, Solaria Energia, Novo Nordisk, Eli Lilly, Vanguard FTSE All-World ETF (WKN: A2PKXG). Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

(0:00) Introducing Eli Lilly CEO Dave Ricks (1:43) How Eli Lilly discovered the GLP-1 impact on weight loss, counterfeit products from China (7:08) GLP-1 pricing and capital allocation after a breakout pharma product (12:56) Why Biotech VC has plummeted, “patent hacking” in China (15:32) Dave's health regimen: good sleep, movement, healthy diet, social relationships, reading (18:32) Unexpected impacts of GLP-1s, helping with addictions, potential mental health use cases (21:16) Thoughts on RFK Jr, Big Pharma's influence on the media, how AI empowers patients (25:27) Impact of proposed NIH cuts, explaining the “PBM boogeyman”, next major pharma breakthrough Thanks to our partners for making this happen! Solana - Solana is the high performance network powering internet capital markets, payments, and crypto applications. Connect with investors, crypto founders, and entrepreneurs at Solana's global flagship event during Abu Dhabi Finance Week & F1: https://solana.com/breakpoint OKX - The new way to build your crypto portfolio and use it in daily life. We call it the new money app. https://www.okx.com/ Google Cloud - The next generation of unicorns is building on Google Cloud's industry-leading, fully integrated AI stack: infrastructure, platform, models, agents, and data. https://cloud.google.com/ IREN - IREN AI Cloud, powered by NVIDIA GPUs, provides the scale, performance, and reliability to accelerate your AI journey. https://iren.com/ Oracle - Step into the future of enterprise productivity at Oracle AI Experience Live. https://www.oracle.com/artificial-intelligence/data-ai-events/ Circle - The America-based company behind USDC — a fully-reserved, enterprise-grade stablecoin at the core of the emerging internet financial system. https://www.circle.com/ BVNK - Building stablecoin-powered financial infrastructure that helps businesses send, store, and spend value instantly, anywhere in the world. https://www.bvnk.com/ Polymarket: https://www.polymarket.com/ Follow the besties: https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg Follow on X: https://x.com/theallinpod Follow on Instagram: https://www.instagram.com/theallinpod Follow on TikTok: https://www.tiktok.com/@theallinpod Follow on LinkedIn: https://www.linkedin.com/company/allinpod Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg

Melt Away Fat! Never Diet Again!! The promises of “magic pills” that will lead to safe, effortless weight loss are everywhere. But while these mythical weight loss products may never exist…the FDA is getting ready to approve something extremely close. The news has been nearly impossible to miss…with a tidal wave of interest in medications that are revolutionizing an innovative approach to weight loss is swiftly evolving. Unlike past diet and weight loss trends, GLP-1 drugs are generating levels of enthusiasm that have rarely been seen. And honestly, there are few examples from history that have generated such impact. What once started as a lesser-known treatment (aiming to control blood glucose levels) of type-2 diabetics has turned Ozempic, Wegovy, Mounjaro, and Zepbound into household names, and brought us to the cusp of a health revolution. Furthermore, the next few days, months, and beyond, are shaping up to be a pivotal time for the GLP-1 landscape…mostly due to the FDA expectantly approving the first orally administered medication for chronic weight management (i.e. oral Wegovy semaglutide) sometime during this fourth quarter of 2025. Though, if this discovery has fueled an unprecedented surge in interest and demand for these current injectable peptides, why then are companies working so hard to make oral tablet forms of weight loss drugs that target the GLP-1 receptor? From a business perspective, there are some obvious advantages…such as oral tablet formulations tend to be cheaper and easier to manufacture and distribute than sterile injector pens. In fact, manufacturing complexity, both in terms of making the peptide active ingredients and producing the final injectors…significantly contributed to both Eli Lilly and Novo Nordisk struggling to supply surging demand for their products following approvals for weight loss indications. And from a patient perspective, oral weight loss pills are attractive for several reasons…most notably enhancing convenience for those who simply prefer pills to injections and making treatment accessible to those who are “extremely needle-phobic.” However, while tablet forms are generally more familiar and accessible to most individuals, the relative success of any oral drugs will likely depend on a combination of price, performance, and side-effect profiles. And although oral Wegovy is expected to be approved first, competition will quickly heat up from a myriad of biopharma companies, including Eli Lilly, Viking Therapeutics, Biomed, and Roche. In fact, Eli Lilly is expected to submit its application soon to the FDA for its once daily oral weight loss drug (with potential regulatory approval in 2026). Regardless, the demand for effective weight loss treatments is huge…and there's ample space in the market for a variety of complementary therapies. According to recent Goldman Sachs projections, the U.S. weight loss medication market will essentially triple to over $60 billion by 2030…with oral versions accounting for a quarter of that total market size. While oral weight loss drugs represent (in my opinion) one of the most significant new product cycles across the entire biopharma sector, there's no guarantee they make an immediate disruptive market impact or outcompete existing injectables long-term. And these will be margin accretive for the pharmaceutical industry's newest cash cow…even if this first wave isn't perfect, there will be a next wave of improvements, and then another new wave of improvements after that (if appropriate).

Welcome back, listeners, to Ozempic Weightloss Unlocked. Today, we are uncovering the latest news and updates on Ozempic, from its medical applications to its influence on our daily lives and overall health.There is an exciting development in the world of weight loss medication: a pill form of Ozempic, known by its generic name semaglutide. According to The New England Journal of Medicine, those who took the daily semaglutide pill lost nearly fourteen percent of their body weight over sixty-four weeks, compared to just two percent for those who took a placebo. This makes oral semaglutide a potential game changer for those who prefer pills over injections, especially since the pill shows a safety profile similar to the injectable form. Dr. Sean Wharton, who led the recent clinical trial, explained that this oral option could greatly expand the number of people willing to try GLP-1 treatments for obesity.Following closely behind is orforglipron, a new GLP-1 pill developed by Eli Lilly. Fox News reports that in a recent clinical trial, participants taking the highest dose of orforglipron lost an average of more than twenty-seven pounds after a year and a half. Nearly sixty percent of those participants lost ten percent of their body weight, while just under forty percent lost at least fifteen percent. What is even more hopeful, according to the study published in The New England Journal of Medicine, is that those with pre-diabetes saw a sharp improvement in blood sugar levels, suggesting broad metabolic benefits. While the results are compelling, experts note that injectables like Ozempic still deliver slightly more dramatic results, yet many patients may prefer the convenience and ease of a pill.On a different front, research from The Cleveland Clinic has revealed that genetics may influence just how well Ozempic or similar drugs work for you. According to their study, a gene known as Neurobeachin appears to help determine how much weight a person might lose with GLP-1 medications. People with a responsive version of the gene were eighty-two percent more likely to have significant weight loss, while those with a non-responsive score were actually less likely to lose weight. Dr. Daniel Rotroff from the Cleveland Clinic suggests that in the near future, doctors could combine genetic testing with lifestyle and personal factors to tailor obesity treatment, making these therapies even more effective and personalized.Let us not forget the reason why Ozempic was developed in the first place. Originally designed and approved to help manage type two diabetes, Ozempic as well as its higher-dose sibling Wegovy, are now also used for chronic weight management. Both are part of a class called glucagon-like peptide-1 receptor agonists, or GLP-1s. These medications work by stimulating insulin production and helping the body manage appetite and digestion, leading to weight loss as a beneficial side effect. According to information from the Lawsuit Information Center, Ozempic is still mainly prescribed as a once-weekly injection, but with oral versions nearing approval, that could soon change.New treatments often come with questions about safety. According to the United States Food and Drug Administration, there has been increased concern about unapproved compounded versions of these GLP-1 drugs, which have been linked to hundreds of adverse event reports. This highlights the importance of using only medications that are properly prescribed and approved, as safety must always come first.Finally, there are ongoing investigations into rare but serious side effects, such as a risk of vision loss, and digestive issues like gastroparesis linked to GLP-1 drugs including Ozempic. For most people, side effects tend to be mild and include nausea and digestive discomfort, but it is crucial to talk to your doctor to understand the potential risks and benefits as this new generation of weight loss options emerges.That wraps up our update on Ozempic and the evolving world of GLP-1 weight loss therapies. Thanks for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe for more insights, and as always, stay informed and stay healthy. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

I wanted this conversation to do two things at once. First, ground the hype in real practice. Second, show how a small country can punch well above its weight by connecting industry, academia, and government with purpose. With Chantelle Kiernan from IDA Ireland and Stephen Flannagan from Eli Lilly and Company, we explored what digital transformation really looks like on the factory floor in Ireland, why talent is the engine behind it, and how cross-sector collaboration is turning ideas into measurable outcomes. Ireland's manufacturing base employs hundreds of thousands and fuels exports, yet what stands out is the shared mindset. The shift toward Industry 5.0 puts people at the center while using digital, disruptive, and sustainable technologies to rethink production. Eli Lilly's experience shows how a digital-first culture changes everything. New sites start paperless by default. Established plants raise their game through micro-learning, data-driven problem solving, and champions who model the behavior. The message is simple. Technology only sticks when people see clear value and have the skills to act on it. From pilots to site-wide change Here's the thing. The strongest wins come from a strategic, site-wide approach rather than isolated pilots. Maturity assessments across pharma sites in Ireland revealed common patterns, shared bottlenecks, and repeatable opportunities. That insight helps teams justify investment, sharpen ROI arguments, and accelerate adoption without slowing production. Reinvestment in legacy facilities becomes a long-term advantage when you connect equipment, data, and people with a clear plan. This is where Ireland's ecosystem shows its class. Purpose-built centers like Digital Manufacturing Ireland, NIBRT, IMR, and I-FORM give teams a place to test before they invest. Indigenous tech SMEs sit at the same table as global pharma leaders and large tech firms, which means collaboration moves faster. When 50 percent or more of new R&D projects cite academic partnerships, you know something healthy is happening. Skills, STEM, and the mindset shift Upskilling came through as the decisive enabler. IDA Ireland supports companies with skills needs analysis and access to training. Universities co-create relevant courses. Micro-credentials and immersive apprenticeships build confidence on the shop floor. Stephen's point about micro-learning hit home. People learn best when they can apply knowledge to a problem they care about, right now. That keeps momentum high and spreads digital competence across teams without waiting on giant projects. Barriers still exist. Defining ROI, coping with regulatory complexity, and balancing change with daily production are real challenges. Culture is the swing factor. Leaders who set the tone, create space for experiments, and reward progress see faster results. GenAI is already shifting attitudes by improving personal productivity, which naturally opens minds to operational use cases like predictive maintenance, knowledge capture, and quality improvements. What comes next If the last decade was about connecting machines, the next decade will be about connecting knowledge. Expect smarter, greener, and more multidisciplinary manufacturing. AI will sit alongside advanced materials and sustainable design. The most resilient sites will combine agile infrastructure with strong learning cultures, so they can absorb change rather than resist it. Ireland's model of collaboration gives a useful signal. When industry, government, and academia align around shared outcomes, the runway gets longer and the takeoff gets smoother. This episode is about the practical choices that make transformation real. Strategic assessments. Shared R&D spaces. Cohorts of digital champions. And a relentless commitment to skills. It is a story of steady progress that scales, and a reminder that the future belongs to teams who can learn faster together. ********* Visit the Sponsor of Tech Talks Network: Land your first job  in tech in 6 months as a Software QA Engineering Bootcamp with Careerist https://crst.co/OGCLA

In this episode of “This Is Purdue,” we're talking to Dimitri Peroulis, senior vice president for partnerships and online at Purdue and the Reilly Professor of Electrical and Computer Engineering.   As an executive leader, he guides the university's online programs and the offices of Industry Partnerships, Global Partnerships and Engagement. He's also an expert on Purdue's innovative degrees and courses for workforce development and advancement that prepare students to stay “future-ready.” And he brings a wealth of technical knowledge and teaching experience to the ever-evolving higher ed landscape.  In this episode, you will:   Hear about Purdue's strategic relationships with corporate partners like Eli Lilly and Company and Wabash and how they're enhancing student workforce preparation through research, internships and alumni mentorship. Discover what it means to be “future-ready” and what experiences students need to be flexible, resilient problem-solvers as they enter a changing workforce. Learn more about Purdue University Online's new and expanded degree programs and microcredentials that didn't exist 10 years ago, including the first and only ABET-accredited AI certifications and microelectronics and semiconductors certifications.   Explore how these unique virtual programs and certificates are helping thousands of students balance their lives as full-time professionals and thrive in the classroom and industry experiences.   Find out more about Dimitri's journey growing up and studying in Greece to later winning Purdue's Charles B. Murphy Outstanding Undergraduate Teaching Award.   You don't want to miss this episode with an award-winning educator and thought leader who's helping empower Purdue students with the skills they need to solve today's toughest challenges.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome to The Peptide Podcast. In this episode, we're unpacking the latest on retatrutide and how it measures up against semaglutide and tirzepatide.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  https://pepties.com/partners/ We'll look closely at what the studies tell us so far — from overall weight loss to reductions in visceral fat and how much lean muscle mass is preserved. We'll also talk about where the evidence is solid, where it's still developing, and why cross-trial comparisons should be made with caution. What is retatrutide? So let's start with the basics—what is retatrutide? Retatrutide is a new type of weight-loss medication called a triple agonist. That sounds fancy, but what it really means is that it targets three hormone receptors in the gut and pancreas: GLP-1, GIP, and glucagon. Each of these plays a slightly different role in metabolism and appetite regulation. To break it down: GLP-1, which you might already know from drugs like semaglutide, mainly slows digestion, helps you feel full, and improves insulin sensitivity. GIP, which tirzepatide targets along with GLP-1, also helps regulate blood sugar and may improve how the body stores and burns fat. Retatrutide adds glucagon receptor activation on top of that, which seems to further boost fat burning. So how does this compare to semaglutide and tirzepatide? Semaglutide is a GLP-1-only drug, so it mainly works by reducing appetite and slowing gastric emptying. Tirzepatide is a dual agonist, hitting GLP-1 and GIP, which gives it a slightly stronger effect on blood sugar control and fat metabolism compared to semaglutide. Retatrutide goes one step further by adding glucagon activity, potentially giving more total fat loss. In other words, you can think of it like a spectrum: semaglutide hits one target, tirzepatide hits two, and retatrutide hits three—each additional receptor seems to enhance metabolic effects and fat loss in clinical trials. That's why people are excited about retatrutide, though it's still early, and we're waiting on larger studies to see exactly how it compares head-to-head with the others. And that's going to be key, since right now we don't have direct comparisons to other advanced therapies like semaglutide or tirzepatide in the published Phase 2 data. How does retatrutide compare to semaglutide and tirzepatide? Total body weight loss: Now let's put these three medications side by side and look at what the trials actually tell us about total body weight loss. Starting with retatrutide: in its Phase 2 obesity program, the numbers were unusually large, especially given the relatively short trial window. In the 48-week study, people on the higher doses—8 or 12 milligrams weekly—lost about 22 to 24% of their body weight on average. That's the result that really made headlines. It's worth noting that some trials report slightly different averages depending on the group studied—people with obesity but no diabetes versus people with type 2 diabetes—but across the board, that 48-week signal is consistently very strong. For comparison, let's step back to semaglutide at the 2.4 mg dose, which was tested in the pivotal STEP-1 trial. Over 68 weeks, participants lost about 15% of their body weight on average. That was a landmark finding when it was published in the New England Journal of Medicine—it essentially set the modern benchmark for what a GLP-1 monotherapy could do. Then we have tirzepatide, the dual GIP and GLP-1 agonist. The SURMOUNT-1 trial, which ran for 72 weeks, showed dose-dependent results: about 15% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to only around 3% with placebo. Other obesity studies with tirzepatide have backed this up, especially at the higher doses. And in head-to-head comparisons with semaglutide, tirzepatide has consistently come out on top. So if we zoom out: retatrutide's Phase 2 data suggest the greatest average reductions—over 22%—in less than a year. Tirzepatide follows closely behind with around 21% over 72 weeks. And semaglutide shows very meaningful, but smaller, weight loss of around 15% over a similar time frame. The big caveat here is that these aren't perfect apples-to-apples comparisons. The trials differed in their length, the types of patients enrolled—some had type 2 diabetes, some did not—their baseline weights, and even the way results were reported. Plus, retatrutide is still in Phase 2 for obesity, whereas semaglutide and tirzepatide already have large Phase 3 programs and real-world data backing them up. Visceral fat reduction: Next, let's talk about visceral fat reduction—that's the deep fat that surrounds organs like the liver, pancreas, and intestines. It's particularly important because high levels of visceral fat are strongly linked to cardiometabolic disease. Starting with retatrutide, one of the Phase 2 substudies used DEXA scans to measure body composition in detail. At the higher doses—8 and 12 milligrams per week—participants saw visceral fat drop by about 29 to 31% over 48 weeks. That's a very large relative reduction in under a year and one of the reasons people are excited about retatrutide's potential not just for weight loss, but also for improving long-term metabolic health. How does that compare to the other drugs? With semaglutide, we also have DEXA and imaging substudies from the STEP program and follow-up mechanistic work. These consistently show meaningful visceral fat reductions, along with improvements in the ratio of lean to fat mass. The difference is that semaglutide studies typically report VAT changes as “significant and clinically relevant,” but they don't always publish one clear headline number that's directly comparable to retatrutide's ~30%. In other words, semaglutide definitely lowers visceral fat, but depending on the study and population, the exact percentage looks different. For tirzepatide, we also have imaging-based data from the SURMOUNT trials and related body-composition studies. These show that the majority of weight lost is fat mass—including a significant portion of visceral fat. Some analyses report reductions on par with what's seen with GLP-1 therapies, while others suggest tirzepatide may push a bit further. But again, the actual percentages vary depending on whether the study used DEXA, CT, or MRI, and on who was enrolled. The big caveat here is that we don't yet have a head-to-head imaging study comparing all three drugs in the same population with the same methods. Retatrutide's ~30% visceral fat drop is certainly eye-catching, but without that kind of standardized comparison, it's hard to say definitively whether it's truly better than semaglutide or tirzepatide. Lean muscle mass preservation: Now let's shift to lean mass preservation, which is just as important as total weight or fat loss. Across all of the modern obesity drug trials, one thing has been consistent: most of the weight people lose is fat, but some lean tissue is lost too. That's expected whenever you're in a sustained calorie deficit. The question is how much muscle is preserved, and how the proportions break down. With retatrutide, the DEXA substudy showed something reassuring. Even though people lost a lot of total weight and fat, the proportion of lean mass lost compared to total weight loss was similar to what we see with other therapies. In other words, the drug seems to drive large fat reductions without causing disproportionate muscle loss. Interestingly, the absolute amount of lean tissue lost in kilograms was pretty stable across different doses, even though fat loss varied quite a bit. That suggests the extra weight loss with higher doses is really coming from fat, not muscle. Looking at semaglutide, the STEP trials with DEXA scans reported the same general pattern. People lost more fat than lean mass, and when you adjust for the total weight loss, body composition actually improved. In fact, some analyses showed a slight increase in the percentage of body weight that was lean tissue, even though the absolute lean mass in kilograms went down. So again, it's not that muscle isn't affected—it is—but fat loss makes up the majority of the change. For tirzepatide, the SURMOUNT body-composition studies found that about 75% of the weight lost is fat and about 25% is lean mass. That split is very similar to what was seen in the placebo groups, which means the drug isn't shifting the balance unfavorably. It preferentially reduces fat, while lean mass preservation is in the same ballpark as semaglutide and retatrutide. Now, here's the important nuance: lean mass on a DEXA scan isn't just skeletal muscle. It includes water, organ tissue, and other components. So if someone loses 3 or 4 kilograms of “lean mass,” we don't know how much of that is functional muscle versus water or smaller organ size. That's why these numbers can be misleading if you take them at face value. And this is where lifestyle comes in. Resistance training and adequate protein intake are critical alongside medication. Lifting weights or doing bodyweight resistance work helps preserve functional muscle, while getting enough protein—typically somewhere in the range of 0.8 to 1 gram per pound per day depending on age and activity—supports muscle repair and maintenance. Every trial we've seen shows that the best outcomes, in terms of maintaining strength and function, come from pairing these drugs with exercise and nutrition strategies. That way, the unavoidable lean mass changes have far less impact on long-term metabolic health and performance. Limitations, biases, and what's missing (the critical context). No large, peer-reviewed head-to-head trials (yet) comparing retatrutide with semaglutide or tirzepatide for the same endpoints using identical imaging protocols. Most comparisons are cross-trial and therefore imperfect. Retatrutide Phase-2 was often compared to placebo or dulaglutide (in the T2D DEXA substudy) rather than to semaglutide or tirzepatide. A head-to-head (planned/registered) study vs tirzepatide is listed on ClinicalTrials.gov but results are not published yet. Different populations & durations. Some retatrutide data come from cohorts that include people with T2D or NAFLD; semaglutide STEP trials were often in people with obesity (without diabetes) and run longer (68 weeks), while tirzepatide SURMOUNT trials ran to 72 weeks. These differences change the absolute and percent outcomes. Funding and reporting bias. Many of the early retatrutide analyses are industry-funded (Eli Lilly), which is standard for drug development, but it requires us to carefully read methods, endpoints, and completeness of reporting. Independent replication and Phase-3 confirmation matter. Imaging method variation. VAT reported by DXA vs MRI vs CT are not directly interchangeable. Some trials report VAT area, others percent change; that complicates cross-trial percent comparisons.  Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend. Until next time, be well, and as always, have a happy, healthy week.

Hij is vaak voorspeld. Door autojournalisten, door analisten. Telkens wist Elon Musk hem te ontwijken, maar nu lijkt dat lastig. Techbedrijf Xiaomi, slechts een jaar bezig, zou dan toch echt dé Tesla-killer worden.De Chinese autobouwer wil showrooms openen in Europa en zelfs ook auto's willen bouwen op ons continent. Deze aflevering kijken we wat dat voor autobouwers (en Tesla in het specifiek) betekent. Ook duiken we in het aandeel van Xiaomi. Dat is in 12 maanden met bijna 200 procent gestegen.Hebben we het ook over Apple. Dat wil dat Brussel de regels aanpast. Volgens eigen zeggen is de wet digitale markten niet goed voor gebruikers, maar het lijkt er op dat Apple vooral zelf last heeft van de wet.Intel heeft op zijn beurt weer wat nodig van Apple. Geld en een samenwerking om precies te zijn. Rupsje Nooitgenoeg wil namelijk nog meer centjes bij (oud) klanten ophalen.Verder bespreken we het onderzoek dat Brussel doet naar SAP, een Amerikaans onderzoek naar Philips en hun concurrenten, TKH dat iets afsplitst (of toch niet) en je hoort meer over Trump die 'gesaboteerd' wordt. See omnystudio.com/listener for privacy information.

The boss of Eli Lilly has branded the UK “probably the worst country in Europe” for drug prices, US President Donald Trump hit out at the UN at a speech at the global body's General Assembly, and the Federal Reserve has scope to cut interest rates another three times, the OECD has said. Plus, the biggest US-listed companies keep talking about artificial intelligence, but few appear to be able to describe how the technology is changing their businesses for the better. Mentioned in this podcast:Eli Lilly boss brands UK ‘worst country in Europe' for cheap drug pricesCan the UN save itself from irrelevance?Federal Reserve has room for three more rate cuts as US growth slows, says OECDUK set for highest inflation in G7, says OECDAmerica's top companies keep talking about AI — but can't explain the upsidesUntil 29th October, you can save 40% on a standard annual digital subscription at ft.com/briefingsaleCREDIT: PBS and the White HouseRead a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

The news of Texas covered today includes:Our Lone Star story of the day: More murderous terrorism on our country today committed in Dallas. The murderer is dead, identified, and early evidence shows it is likely more Leftist violence against law and order.Our Lone Star story of the day is sponsored by Allied Compliance Services providing the best service in DOT, business and personal drug and alcohol testing since 1995.DC Swamp wants you to know that Cornyn is their man for Senate: Cornyn nabs endorsements from 15 former GOP congressmen.Republican Party of Texas to consider censures of 10 lawmakers made by county party organizations.A strong win for private property rights in Texas over avaricious local government officials. You can't take it just because you might need it in the future.$6.5 billion+ investment and more than 600 new jobs in Harris County from new Eli Lilly facility.Listen on the radio, or station stream, at 5pm Central. Click for our radio and streaming affiliates.www.PrattonTexas.com

Sundhed er en samfundsmæssig megatrend, men investeringsmæssigt har det ikke været interessant i 2025 indtil videre. Sektoren halter godt og grundigt efter resten af markedet, og Millionærklubben undersøger i dagens program hvorfor. Vi diskuterer også om sektoren er en attraktiv investeringsmulighed lige nu, og så tager vi temperaturen på fedmemarkedet, Novo Nordisk og Eli Lilly efter sidste uges diabeteskonference i Wien. Med i studiet er aktiechef i HC Andersen Capital Michael Friis Jørgensen og adm. direktør i Global Health Invest Claus Johansen. Vært: Adam Geil See omnystudio.com/listener for privacy information.

The FDA is working to reapprove GSK's long-dormant drug Wellcovorin (leucovorin) for cerebral folate deficiency, which the agency linked to “developmental delays with autistic features.” This immediately followed a much-anticipated press conference in which President Donald Trump, flanked by Health Secretary Robert F. Kennedy Jr and other healthcare administrators, linked the use of Tylenol during pregnancy to rising rates of autism.  Meanwhile, Pfizer woke us all up Monday with the news that it had acquired breakout obesity rockstar Metsera for $4.9B. The deal should pump new life into Pfizer's portfolio, which over the last two years has suffered three discontinued assets. Bite-sized deals—or those at or below the $5 billion mark—have defined biopharma recently, with Roche picking up metabolic dysfunction-associated steatohepatitis biotech 89bio for a potential $3.5 billion last week and Novartis putting another $5.7 billion on the line with partner Monte Rosa Therapeutics in a second molecular glue agreement.  Another therapeutic space primed for M&A action is psychedelics. After AbbVie bought Gilgamesh Pharmaceuticals' lead depression asset for $1.2B last month, BioSpace spoke sought opinions from experts on who might be next to take the plunge. A few potential names included Eli Lilly, Bristol Myers Squibb and Merck.  On the policy front, the CDC's revamped vaccine advisory committee convened for their first meeting to discuss COVID-19, MMRV and hepatitis B vaccine schedules. Industry watchers who spoke to BioSpace commented on the “lack of knowledge” and dearth of previous experience on the committee. And while the advisors ultimately voted to change the schedule for the MMRV vaccine, it appears unlikely to significantly affect manufacturers' bottom lines. Finally, in rare disease, Stealth BioTherapeutics secured its long-sought approval for elamipretide—now Forzinity—in Barth syndrome—a disorder that would fall under the purview of the FDA's new Rare Disease Evidence Principles framework for ultra rare diseases affecting less than 1,000 people in the U.S. And we said “Bye Bye Bluebird,” as the famed gene therapy biotech—which was recently bought out by two private equity firms—returned to its original moniker, Genetix Biotherapeutics.  Lastly, make sure to sign up for Biopharm Executive here for access to a special deep dive into China biopharma.  

In this episode, Thomas Fuchs, Chief AI Officer at Eli Lilly, shares his journey from early machine learning research to spearheading transformative AI initiatives across the pharmaceutical value chain. Lilly is running over a thousand AI projects—from drug discovery and development to manufacturing and commercial operations—leveraging innovations like language models for chatbots, computer vision for quality control, and biomarker development. Thomas emphasizes trust, transparency, and collaboration as critical to AI adoption, supported by AI certification programs for all Lilly technology employees, as well as AI education resources being made available for everyone at Lilly. He also highlights the company's unique “lab-in-the-loop” setups that generate synthetic data to accelerate innovation. Thomas shares real-world successes, including AI-assisted drug discovery and intelligent chatbots, and how AI is building confidence across the organization. With robust data infrastructure and scalable strategies for synthesizing large datasets, Lilly is driving rapid innovation. Thomas predicts faster drug design, broader access to medicines, and continuous education as defining trends for AI in healthcare. Take a listen.

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Nando Sommerfeldt über die große Parkinson-Wette von Bayer, den BYD-Abschied von Warren Buffett und die unglaubliche Mag7-Bilanz. Außerdem geht es um Pfizer, Metsera, Eli Lilly, Novo Nordisk, Porsche Automobil Holding SE, Porsche AG, Volkswagen, Berkshire Hathaway, BYD, Taiwan Semiconductor, Amundi MSCI USA Daily (2x) Leveraged ETF (WKN: A0X8ZS), WisdomTree Nasdaq 100 3x Daily Leveraged ETP (WKN: A3GL7E), WisdomTree Dax 3x Daily Leveraged ETP (WKN: A1VBKS), Invesco Nasdaq 100 (WKN: 801498). Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article104636888/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Scott Zari says we're in the "very early stages" of the weight loss market. He points to Eli Lilly (LLY) as the market leader but notes Novo Nordisk (NVO) as a strong competitor, especially as it develops a Wegovy pill to compete against Eli Lilly's Zepbound. Scott also touches on Pfizer's (PFE) acquisition of Metsera (MTSR) and called it Pfizer's true way of entering the GLP-1 market after its pill failed.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Dat ABN Amro een overnameprooi was, daar werd al langer over geroddeld. Maar het blijken de Belgen die er wel interesse in hebben. De Belgische concurrent KBC overweegt volgens Bloomberg een overname. Er is nog wel één discussiepunt binnen de Belgische bank: hoeveel hebben we ervoor over? Het onderzoek daarnaar zou nog in een vroeg stadium zijn, maar beleggers sorteren er wel alvast op voor. Of we er serieus rekening mee moeten houden dat ABN Amro binnenkort van onze AEX vertrekt, dat hoor je deze aflevering. Diezelfde AEX is sinds vandaag trouwens een stukje groter. Er zitten nu 30 bedrijven in, in plaats van 25. Al wordt er op die eerste dag van de uitbreiding alweer gespeculeerd hoe lang de zaken zo blijven, want op de aandelen Just Eat Takeaway en JDE Peet's staat alweer een 'verkocht'-bord. Wij speculeren lekker mee wie er dan vervolgens weer een plekje in de hoofdindex verdienen. En we vertellen je ook nog waarom Warren Buffet uit de Chinese autobouwer BYD stapt én wat hij eraan verdiend heeft. We onderzoeken hoe ver de bodem reikt voor bodemonderzoeker Fugro. En je hoort waarom een bedrijf dat nog helemaal niks verkoopt, toch ruim 60 procent hoger staat op de Nasdaq vandaag. See omnystudio.com/listener for privacy information.

What's really in your tap water? This episode breaks down PFAS, lead, and microplastics and why tap water safety is a growing concern. Then FloWater CEO Rich “Raz” Razgaitis explains the science of 7-stage purification: RO at 0.0001 microns, advanced carbon, and remineralization for taste and hydration. If you're evaluating a PFAS water filter for schools, an office water dispenser, or a gym refill station, here is a practical field guide, plus bottled water alternatives that reduce waste. (Also called bottle filling stations or water bottle refill stations.)This episode covers: • How contaminants get past aging infrastructure • Why RO alone isn't the full story (remineralization matters) • Refill stations vs fountains: speed, hygiene, behavior change (~9s vs ~35s) • Practical steps for parents, PTAs, and facilities to launch a pilot fast⏩ Jump to your favorite parts: 00:00 - Welcome to Conscious Design Podcast 00:43 - Introducing Rich “Raz” Razgaitis and FloWater 01:16 - The Origin Story of FloWater 02:58 - The Problem with Tap Water 06:56 - FloWater's Solution 11:24 - Advocating for Clean Drinking Water 24:35 - Future Plans for FloWater 30:28 - Conclusion and Contact InformationAbout Rich “Raz” Razgaitis and FloWaterRich “Raz” Razgaitis is the CEO and Co-Founder of FloWater, a Denver-based company focused on tap water safety and better hydration. After early roles at J&J and Eli Lilly, Raz led several growth-stage companies, including scaling Univera from $35M to $100M in annual revenue. Recognized as EY Entrepreneur of the Year (Mountain West) and a TEDx speaker, Raz co-founded FloWater in 2013 to deliver clean, great-tasting water where people refill most: schools, gyms, hotels, and offices.FloWater Refill Stations use 7-stage purification with RO at 0.0001 microns, advanced carbon, and remineralization. FloWater states its systems remove up to 99.9% of contaminants such as lead, PFAS, and microplastics, and reports saving 1B+ plastic bottles from the environment. Trusted by 10,000+ locations, including Google, Hyatt, Xponential, and Oakland Unified School District.

VPM News Host Lyndon German and BizSense Reporter Jack Jacobs discuss the top business stories in the Richmond region. This week's news includes a billion-dollar investment in Goochland County, the redevelopment of Creighton Court, Henrico County's Best Products property and a new vegan takeout spot coming to Cary Street.

Joel Sauer and I met at a Beyond Monumental team outing and I was thrilled to meet the man behind the Indy Half at Fort Ben. I had to hear how it came together! During this episode, sponsored by Cure Hydration, we talk about:Celebrating 30 years of the Indy Half at Fort BenGoing on 25-50 mile bike rides in his early teenage years and getting into triathlons at age 19 Choosing to go to school at Bradley in Illinois and how he ended up at Eli Lilly when he is a civil engineerHow he completed three Ironman races before he ran his first standalone marathonThe story of starting a marathon in Indianapolis - what is now the Indy Half at Fort BenHow he used his marathon training route as the inspiration for the course Unintentionally qualifying for the 100th Boston Marathon Which of his kids run (he has five kids!)How he has one event on his personal calendar per year to challenge himself - i.e. adventure racesWhat adventure racing is (not an obstacle course)The importance of knowing people's namesWhat he wants runners to know about starting a race or being a race directorHow he did a FULL IRONMAN as a workout last month (his first time covering the distance in 18 years)Upcoming Indy Races:9/20 - Monumental Kids 5K9/27 - Mill Race Marathon 10/3 - "SHAKE IT OFF" Shake Out Run10/4 - Indy Half at Fort Ben 11/8 - Monumental Marathon Sponsor Details:Cure Hydration - Use code ALLYB for 20% off your first orderThis is a SandyBoy Productions podcast.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly's oral weight loss pill, orfoglipron, has faced challenges in meeting expectations, possibly due to an over-representation of males and Hispanic patients in the phase III study. The company is now presenting detailed late-stage data to paint a competitive profile for the drug. Meanwhile, the FDA has targeted Lilly and Novo Nordisk for downplaying risks of their GLP-1 weight loss drugs in advertising, particularly during a prime time special with Oprah Winfrey. Lilly is also investing in a $5 billion manufacturing plant in Virginia, part of a larger $27 billion U.S. investment plan.In other news, GSK is committing $30 billion to boost R&D and manufacturing operations in the U.S., showing a strong commitment to innovation. Additionally, advancements in AI-driven antibody discovery technology by Sino Biological are revolutionizing the field of biotechnology. The pharmaceutical industry is facing tightening oversight and regulatory changes, as well as exploring predictive care powered by consumers and AI technology.This dynamic landscape highlights the importance of staying informed and adaptable in the ever-evolving world of Pharma and Biotech.

Interview: Dr Eric Topol (Part 2) In the second half of our conversation, Dr Eric Topol discusses AI's promise in reducing clinician burnout, forecasting disease, and reshaping prevention. He also reflects on 13 years since The Creative Destruction of Medicine, shares his favourite transformative tools, and offers advice for clinicians seeking creative careersAustralian CDC – the data angle Australia is finally moving ahead with its own Centre for Disease Control, promising better national coordination and public health data sharing. But will it deliver transparency and timely insights—or just more bureaucracy?AI & Fertility – SpermSearchAI delivers first UAE pregnancy An AI tool developed in Australia, by NeoGenix Biosciences, has achieved its first pregnancy in the UAE. The technology speeds up and improves IVF outcomes, showing how Australian health innovation is going global.US Information Blocking Enforcement The US Department of Health and Human Services will finally enforce penalties for health providers and IT vendors who block patient access to their own records. A big step for patient rights, and a reminder of how far Australia still has to go.Apple's Health Tech Push Apple's new Watch Series 11 now measures blood pressure and the latest AirPods can track heart rate. These updates blur the line between wellness gadgets and medical devices, raising big questions about accuracy, equity, and data overload.Eli Lilly's AI Drug Discovery Giveaway Pharma giant Eli Lilly is making its drug discovery language models publicly available through “Lilly TuneLab.” It's part open-science, part strategic play—accelerating research while still funnelling insights back to Lilly.Australian Robotics – Abi the Care Robot Melbourne startup Andromeda has raised $23m to scale Abi, a friendly robot designed for aged care and children's hospitals. Founder Grace Brown, just 25, has quickly become one of Australia's standout young innovators.Resources:Dr Eric Topol's book SuperAgers LinkDr Eric Topol's podcast & substack Ground Truths LinkMedicine and the Machine podcast with Dr Abraham Verghese and Dr Eric Topol LinkBook recommendation: The AI Valley, Gary Rivlin LinkRecommended FREE course: AI in Healthcare from RCSI LinkRecommended FREE course: Patient Insights Masterclass by Savvy Corporate LinkVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

In this eye-opening episode, Dr. Lindsey Elmore exposes the chaos unfolding in the UK as Mounjaro (weight loss/diabetes medication) prices skyrocket 170% overnight—jumping from £92 to £330 per month. Discover how Eli Lilly's "European price matching" triggered panic buying, crashed pharmacy websites, and left patients spending over £1,000 to stockpile medications. Lindsey examines the real-world impact, even in the U.S.: supply shortages, hoarding behaviors, and the unfair advantage given to those who can afford to bulk-buy versus patients with genuine medical needs. A must-listen for understanding how arbitrary pharmaceutical pricing decisions affect real people's access to life-sustaining medications.Main Topic Introduction00:00-00:30: Discussion focuses on Mounjaro (weight loss/diabetes medication) pricing crisis in the UKThe Price Hike00:37-01:13: Massive 170% price increase starting September 1st, 2025Current price: £92/monthNew price: £330/month (up from planned £122/month)01:25-01:41: Eli Lilly justifies increase as "adjusting prices to match the rest of Europe"Pharmacy Response00:37 & 01:41-02:01: UK's largest online pharmacy "Pharmacy2U" freezes prices, then stops sales entirelyPanic Buying Crisis02:09-02:34: Patients stockpiling medications before price hikes02:22: Pharmacies offering 3, 6, or 9-month bundles02:44-02:59: Real examples: patients buying 7-8 pens, spending over £1,000 in panic purchases04:35: Pharmacy websites crashing from demandSupply Chain Impact02:59-03:24: Hoarding strains supply chains and prevents access for patients who truly need the medication03:24-03:44: Medical experts urge against hoarding injectable medications at homeCore Issues Identified03:51-04:12: Access and fairness concerns - distinguishing between medical necessity vs. cosmetic use05:37-05:57: Drug prices change "for no reason at all" with no patient input06:08-06:27: Need to prioritize patients who medically need medications over those who can afford to stockpileSolutions Proposed04:59-05:27: Work with legislators through existing Inflation Reduction Act framework06:27-06:55: Legislative action needed to control "absurd" arbitrary drug pricing, especially for life-sustaining medicationsEpisode Conclusion07:06-07:14: Show closing: encouraging wise health decisionsBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-lindsey-elmore-show--5952903/support.

Dr. Aliza Apple, VP of Catalyze360 AI/ML at Eli Lilly, joins Ross Katz to unveil TuneLab—a first-of-its-kind federated learning platform accelerating preclinical drug discovery. Learn how Lilly's billion-dollar models are empowering early-stage biotechs, the science behind federated learning, and what this means for the future of pharmaceutical R&D. ​​What You'll Learn in This Episode: >> How Eli Lilly's TuneLab democratizes access to proprietary AI models trained on decades of pharmaceutical data >> What federated learning means for IP protection and collaborative data sharing in biotech >> Which two key use cases are driving TuneLab's impact today: small molecule ADME and antibody developability >> How TuneLab's early adopters like Firefly Bio and Superluminal are shaping the platform's evolution >> Why generalizability—not just accuracy—is the true power of collaborative AI in drug development Meet Our Guest Dr. Aliza Apple is VP of Catalyze360 AI/ML at Eli Lilly and a biotech trailblazer with deep roots in AI-driven drug discovery. She has led initiatives from founding startups to heading Lilly Gateway Labs and now pioneers innovation at the intersection of data and biotech. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Aliza Apple  on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Den kompletten Deep-Dive zu Nintendo und noch mehr Analysen von uns hören? Hier 1 Monat kostenlos testen: https://herohero.co/oaws/invites/VVGMROSIUA. Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Dax fällt. Ford streicht Stellen. Spielhallenkette Dave & Busters fällt, aber versucht Turnaround. Continental spaltet ab. Webtoon hat Disney Deal. Thyssenkrupp steigt. Novo & Eli Lilly steigen. Pro7 streicht Prognose. Die Folge zum “Comic Plattform”-Anbieter Webtoon findet ihr hier. Die Firma hinter der Hotel-Kette Premier Inn - Whitbread (WKN: A0LGB1) setzt auf Deutschland und will hier seine Zimmer bis 2030 verdoppeln. Warum Deutschland? Nintendo (WKN: 86409) war in den letzten Jahren ein ziemlicher Highflyer an der Börse. Ist die Aktie mittlerweile zu teuer? Und welches Zukunftspotenzial wird vielleicht unterschätzt? Diesen Podcast vom 17.09.2025, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

To read more of Derek's reporting on GLP-1 drugs, you can subscribe to his Substack here. GLP-1 drugs like Ozempic and Zepbound don't just help with Type 2 diabetes and weight loss. They seem to curb alcohol, cocaine, and tobacco use among addicts. In some studies, they prevent strokes, heart attacks, chronic kidney disease, sleep apnea, and Parkinson's disease. They're associated with a lower risk of several cancers, including pancreatic cancer and multiple myeloma. Arthritic patients on the drugs experienced relief from knee pain that was “on par with opioid drugs.” A small study found that they reduce migraine headaches by 50 percent. And emerging research suggests they might even slow the rate of memory loss among people diagnosed with Alzheimer's. Is all of this real? And if it's real, how is one drug doing so many different things? And if it is doing all those things, why shouldn't we be developing versions of the drug for just about everyone? Today we have two guests: David D'Alessio, chief of endocrinology and metabolism at the Duke University School of Medicine; and Randy Seeley, a professor of surgery, internal medicine, and nutritional sciences at the University of Michigan. We talk about how these drugs work—why they seem to do everything—and how our understanding of them could make them better, more effective, more broadly useful. If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guests: David D'Alessio and Randy Seeley Producer: Devon Baroldi Disclosure: Dr. Seeley has received research support from several pharmaceutical companies, including Eli Lilly, Diasome, and Amgen. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Paul McCulley makes the case for a quarter-point cut at what he calls the "most fraught" FOMC meeting in the past 40 years. Eli Lilly and Novo Nordisk race for the next weight-loss blockbuster drug. Plus, Goldman upgrades a consumer staple.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Lee Brown offers investor insight in the GLP-1 space in what he calls an industry with "expanding opportunity." He believes consumer sentiment has reset to proper expectations following sell-offs in Eli Lilly (LLY) and Novo Nordisk (NVO), anticipating significant upside following the repricing. Tom White offers an example options trade for Eli Lilly.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novartis and Monte Rosa have entered into their second molecular glue deal worth up to $5.7 billion, with Novartis putting $120 million upfront for more of the biotech's AI-discovered degraders. The myasthenia gravis market, once sparse, is now flourishing with new treatments approved and promising late-stage trial results from companies like Argenx and Regeneron. In other news, AstraZeneca has suspended its $270 million commitment in the UK, the FDA has flip-flopped on scrapping advisory committee meetings, and Sino Biological has developed a high-throughput platform for AI-driven antibody discovery. The myasthenia gravis space is heating up with targeted therapies, with several companies releasing promising late-stage trial results. Biogen is developing a pipeline for lupus, with investors showing interest in their programs. The FDA has several actions scheduled for September, including Merck's proposed subcutaneous formulation of Keytruda. Eli Lilly's obesity pill, Orforglipron, is in focus at the European Association for the Study of Diabetes meeting. In the cancer news, Merck's Keytruda challenger faces consistency problems, while other companies like Daiichi Sankyo and Biontech report positive data. Capsida reports a patient death in a gene therapy trial, while Alkermes shows promise in narcolepsy treatment. FDA is looking to streamline the development of non-opioid painkillers. Various webinars and events are upcoming in the pharma industry. Job opportunities are available at companies like Moderna, Abbvie, and Regeneron. Overall, the biopharma industry is seeing advancements and progress in various therapeutic areas.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: kids' A1C and tech access correlation, first generic GLP-1 for weight loss approved, Metformin cuts long covid risk, Tandem Diabetes & Eversense updates, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Accessibility to modern diabetes technology directly correlates with A1c among children with type 1 diabetes globally. Big, cross-sectional study, conducted in 81 pediatric diabetes centers in 56 countries, found that a greater extent of reimbursement for continuous glucose monitoring (CGM), insulin pumps, glucose meters, and insulin was associated with lower A1c levels. Partha S. Kar, MD, Type 1 Diabetes & Technology lead of the National Health Service England, told Medscape Medical News, “As is now being shown in countries such as UK with widespread uptake of technology, there is now population-wide shift in A1c not seen before.”   He added, “If policymakers are serious about bringing A1c at a population level to sub-7.5% - 8% levels, then without technology it would be incredibly difficult to achieve, in my experience and opinion. Leaving the median A1c of a population at above 7.5%-8% goes with complications so that's a decision regarding investment many will have to make in the near future.”   In an accompanying editorial, Elizabeth R. Seaquist, MD, professor of diabetes, endocrinology, and metabolism and co-director of the Institute for Diabetes, Obesity, and Metabolism at the University of Minnesota, Minneapolis, called it “striking” that access to technology in and of itself was associated with improved glycemic control, given that multidisciplinary team care is also needed to provide education and behavioral or psychological support.     https://www.medscape.com/viewarticle/diabetes-tech-access-linked-a1c-kids-t1d-globally-2025a1000nn6 XX A man with type 1 in Illinois has received the first FDA-approved islet-cell replacement treatment, Lantidra, and  he is now producing his own insulin. The treatment works by restoring the body's beta cells, potentially eliminating the need for insulin injections.   The FDA approved Lantidra (donislecel) in 2023. Lantidra uses donor cells and requires lifelong immunosuppressive drugs.     Lantidra is only available at University of Illinois Chicago Health. Other universities, such as the University of Pennsylvania, continue to do islet cell transplants as part of clinical trials. Early data has shown that a majority of participants in the Lantidra clinical study were able to achieve some level of insulin independence, but it's unclear whether the benefits of donislecel outweigh the treatment's safety risks. Nearly 87 percent of participants reported infection-related adverse events, and post-operation complications included liver lacerations, bruising of the liver (hepatic hematoma), and anemia. One patient died of multi-organ failure from sepsis, which Lantidra maker CellTrans stated was “probably related” to the use of either immunosuppression or study drugs.   In addition, some industry leaders have raised the question of whether it's ethical to commercialize the use of deceased donor islet cells. https://diatribe.org/diabetes-research/first-fda-approved-islet-cell-transplant-performed?utm_campaign=feed&utm_medium=social&utm_source=later   XX Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk's injected Saxenda (liraglutide).   The compound, which is a GLP-1 forerunner of Novo's semaglutide products Ozempic and Wegovy, has been approved by the FDA to treat adults with obesity and those who are overweight and have weight-related medical problems.     Saxenda also is endorsed for pediatric patients ages 12 through 17 who are obese and weigh at least 60 kg (132 pounds). The treatment is for both triggering and maintaining weight loss. Saxenda is not the first GLP-1 drug that is available as a generic. In June of last year, Teva also was the first company to launch a knockoff version of Novo's Victoza, which is the same compound as Saxenda but has been approved only for patients with Type 2 diabetes. Sales of the branded versions of both Victoza and Saxenda have declined significantly in recent years as demand for Novo's semaglutide and Eli Lilly's tirzepatide products have skyrocketed. In addition, marketers of compounded products have been aggressively competing for market share in the GLP-1 space. https://www.fiercepharma.com/pharma/saxenda-knockoff-teva-launches-first-generic-glp-1-obesity   XX Metformin could cut the risk of Long COVID by 64% in overweight or obese adults who started the drug within 90 days of infection. The large observational study, published in Clinical Infectious Diseases, analysed health records of over 624,000 UK adults with COVID-19 between March 2020 and July 2023. Among these, nearly 3,000 patients who began metformin treatment soon after diagnosis were tracked for a year. Compared to non-users, their likelihood of developing Long COVID, defined as persistent symptoms 90 days or more after infection, was dramatically lower. https://www.ndtv.com/health/metformin-cuts-risk-of-long-covid-by-64-why-the-diabetes-pill-is-not-for-everyone-9242332 XX Forty-four percent of people age 15 and older living with diabetes are undiagnosed, so they don't know they have it, according to data analysis published Monday in the journal The Lancet Diabetes & Endocrinology. The study looked at data from 204 countries and territories from 2000 to 2023 in a systematic review of published literature and surveys. “The majority of people with diabetes that we report on in the study have type 2 diabetes,” said Lauryn Stafford , the lead author of the study.   “We found that 56% of people with diabetes are aware that they have the condition,” said Stafford, a researcher for the Institute for Health Metrics and Evaluation. “Globally, there's a lot of variation geographically, and also by age. So, generally, higher-income countries were doing better at diagnosing people than low- and middle-income countries.” People under 35 years were much less likely to be diagnosed if they had diabetes than people in middle age or older. Just “20% of young adults with diabetes were aware of their condition,” Stafford said. https://www.cnn.com/2025/09/08/health/diabetes-undiagnosed-half-of-americans-wellness XX A team of Hong Kong scientists is developing an injectable treatment that could potentially improve blood flow in diabetes patients' feet, in the hopes that it will reduce the need for amputation by rebuilding tissue in the arteries.   They also hope to apply the treatment to peripheral artery disease or PAD, a condition caused by the build-up of fatty deposits in arteries that affect blood circulation in the feet. “Traditional treatments for people suffering from poor blood flow in their legs are stent implantation or bypass surgery, which is invasive,” said Wong, who is also the co-founder of a biotechnology company called NutrigeneAI. He said it was his dream to turn research in the academic field into actual clinical treatments. But he added that the team still needed three to four years for further research on the treatment.   https://www.scmp.com/news/hong-kong/health-environment/article/3324671/hong-kong-scientists-developing-new-blood-flow-treatment-aid-diabetes-patients XX   Tandem Diabetes announces Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.   The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.  https://www.businesswire.com/news/home/20250904665715/en/Tandem-tslim-Mobile-App-Now-Authorized-by-Health-Canada-for-iPhone-and-Android-Phones   XX Some changes to how the Eversense CGM will be rolled out.. right now it's being distributed by Ascensia Diabetes Care.  Senseonics will take back commercial control of the year long implantable CGM on January 1 in the US and expanding worldwide throughout 2026. The change was a mutual decision, according to the two companies, which said they have signed a memorandum of understanding before a definitive agreement is hammered out by the end of the year. To get started, Senseonics is also set to acquire members of Ascensia's commercial staff—including its CGM president, Brian Hansen, who is slated to become Senseonics' new chief commercial officer. https://www.fiercebiotech.com/medtech/senseonics-retake-eversense-cgm-commercial-control-ascensia-diabetes-care XX Utrecht-based medical device company ViCentra has closed an $85 million Series D round of funding led by Innovation Industries, along with existing investors Partners in Equity and Invest-NL. The round also drew support from EQT Life Sciences and Health Innovations.   The recent capital injection will be used to expand ViCentra's manufacturing capabilities, support regulatory approvals, and strengthen commercial rollout across Europe.   The funds will also be used to launch the next-generation Kaleido 2 patch pump in Europe and prepare for entry into the U.S. market.   The global insulin delivery market is growing quickly due to the increasing number of diabetes cases and demand for effective and user-friendly solutions. The market for insulin pumps is projected to exceed $14 billion by 2034. Patch pumps are the fastest-growing segment, signalling a trend toward compact and wearable devices. And here's where ViCentra is positioned to meet this need, offering a user-friendly, sleek design-led alternative to traditional systems.   Kaleido: design-led insulin delivery Kaleido is the smallest and lightest insulin patch pump developed as a lifestyle product with a particular focus on usability and personalisation.   Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials, and users can select their own favourite aluminium shells from a range of ten preset colour options.   It integrates with Diabeloop's hybrid closed-loop algorithms (DBLG1 and DBLG2) and is compatible with Dexcom CGM sensors, positioning it within the next generation of automated insulin delivery systems.   “Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honours those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the U.S. market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, Chief Executive Officer at ViCentra.   Improving the quality of life for diabetic patients ViCentra, led by Tom Arnold, is on a mission to improve the lives of those with diabetes.   The company reported that demand for Kaleido in Germany, France, and the Netherlands has already exceeded initial expectations.   ViCentra will present updates on Kaleido at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 15–19, 2025, in Vienna.   The company plans to engage with clinicians, investors, and strategic partners to further its role in the evolving diabetes care landscape.   “ViCentra is redefining insulin pump therapy with a platform that truly centres the user experience – combining clinical performance with design simplicity and wearability,” commented Caaj Greebe, Partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We're proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”   https://techfundingnews.com/dutch-vicentra-secures-85m-to-bring-insulin-patch-pump-to-more-markets/ XX Luna Diabetes announces they've raised more than 23-million dollars in early venture capital to help continue clinical trials and build out its capacity. This is the company that wants to offer a night time only, tiny, temporary insulin pump – to supplement insulin pen use. According to the company, more than 80% of the improvements in blood sugar from automated insulin delivery systems occur while the user is sleeping. Luna launched a pivotal trial late last year. https://www.fiercebiotech.com/medtech/nighttime-insulin-patch-pump-maker-luna-diabetes-raises-236m   XX Following 15 days and 150 fingerpricks, they're here. The results of the “9 sensor samba“. And what a set of a results…   Well maybe that's overplaying it a little.   Let's just say that the outcome of this n=1 experiment wasn't quite what I expected. One of the established players came out much worse than expected, while a newcomer did a lot better.   Let's dig in, and take a look at the variation. https://www.diabettech.com/cgm/the-nine-sensor-samba-results-revealed/   XX Hard work and perseverance define ranch life, but one man in eastern Montana takes it to another level. At 90, he's still living independently on the ranch he built from the ground up. Even more remarkable? He's a type 1 diabetic.   Bob Delp still begins each day just like he did decades ago, waking up on his ranch near Richey, Montana.   “I always thought if I could ever get a ranch and run a hundred cows, that's what I wanted to do from the time I was a kid,” said Delp.   He made that dream real, the hard way; after coming home from the army, he taught school, hayed for seven cents a bale and saved every cent he could.     “I worked at it real hard because I always felt like it was going to be part of getting me to that ranch that I always wanted,” said Delp.   He did it all while managing type 1 diabetes, a diagnosis that came with few answers and little hope back in the 1950s.   “The doctors tell me being a type 1 diabetic for 66 years isn't supposed to happen. Back then, it was a real challenge,” added Delp.   Statistically, it's almost unheard of. Fewer than 90 people in the world have lived more than 70 years with type 1 diabetes.     Bob credits his late wife, Donna, for helping him beat the odds.   “She has been key in that I always ate on time.”   They've faced their share of storms, both in health and out on the land. Not long after moving to Richey, a heavy snowstorm nearly tore everything apart just after they'd stepped out for dinner.   “If Donna hadn't said it was time to eat, we wouldn't have made it out of there. I guess that's one time that made me happy to have diabetes. And I think that saved us,” said Delp.     Now, he still checks his blood sugar daily but trusts his hands more than high-tech insulin pumps.   “I'm not satisfied with the sensors they have today. I just don't think they're accurate.”   To many, Bob's survival is extraordinary. To him, it's luck.   “The genes are there already, I can't change that so I guess I would have to say just lots of good luck,” said Delp.     And through it all, optimism has been his compass.   “You might fumble the ball, but if you're determined to be a winner, you'll recover that fumble someday,” said Delp.   He still welds nearly every day. Not because he has to, but because it keeps him going.   “As long as I keep doing something like this, I will not be in the nursing home,” said Delp.   https://www.kfyrtv.com/2025/08/09/against-all-odds-montana-man-thrives-with-type-1-diabetes-90/ XX Today, Dexcom is building on this belief and breaking new ground with the launch of its first open call across the U.S. and Canada in search of the next diabetes advocates—giving people with all types of diabetes a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale in the company's World Diabetes Day campaign (Nov. 14) and beyond.  Who is eligible?: Anyone age 2+ living with all types of diabetes or prediabetes can be nominated by themselves or by someone who knows them. Selected candidates will embody strength, advocacy and pride in living with diabetes or prediabetes. Where and how can I nominate myself or someone I know?: Visit Dexcom.com/WorldDiabetesDay When is the deadline to submit a nomination?: Nominations are open from September 10 through September 19 at 12pm PT. What will the selected candidates experience?:   An invite to participate in a World Diabetes Day photoshoot in Los Angeles to have their unique story featured in Dexcom's World Diabetes Day campaign The ongoing opportunity to attend events, connect with community, and raise diabetes awareness around the world XX The European Association for the Study of Diabetes (EASD) 2025 Annual Meeting will feature major clinical trial results in type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, several new clinical practice guidelines, and much more. The 61st annual EASD meeting will take place on September 15-19, 2025, in Vienna, Austria.   

RH just the latest company to warn about the impact of tariffs on its earnings. Its CEO adding this is probably the worst housing market in 50 years. Then what could a potential bid from Paramount Skydance for Warner Brothers Discovery mean for the media landscape? And Novo Nordisk prepares for the launch of an oral version of its blockbuster weight loss drug. A look at the competition with Eli Lilly.

Joanna Moncrieff is a British psychiatrist and academic. She is Professor of Critical and Social Psychiatry at University College London and a member of the Critical Psychiatry Network. She is the author of The Myth of the Chemical Cure and The Bitterest Pills, which are considered central texts in the critical psychiatry movement. Moncrieff is critical of mainstream psychiatry's medical model of mental illness. Professor Moncrief's 2022 paper in molecular psychiatry didn't just make waves, it created a tsunami. Leading a systemic review of five decades of research, she and her team definitively demonstrated what no one had dared to state so clearly that there's no convincing evidence that depression is caused by a serotonin imbalance or any chemical imbalance at all. This paper became one of the most widely read scientific papers in modern history, ranking in the top 5 % of all research ever tracked. The world took notice because the world needed to know. Her groundbreaking new book, Chemically Imbalanced, The Making and Unmaking of the Serotonin Myth, meticulously documents how an entire medical narrative was constructed without scientific foundation marketed to billions and defended by institutions that should know better.https://joannamoncrieff.com/2022 paper in molecular psychiatry on Serotonin Chemically Imbalanced: The Making and Unmaking of the Serotonin Myth Dr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

The shock success of GLP-1 treatments for obesity carries massive implications for wealthy societies and manufacturers Novo Nordisk and Eli Lilly alike. In this week's Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot has companies running to keep up. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices

Nel discorso sullo Stato dell’Unione a Strasburgo, Ursula von der Leyen ha invocato maggiore autonomia europea in difesa, energia, tecnologia ed economia. Sull’Ucraina, proposta l’utilizzazione dei fondi russi congelati per prestiti a Kiev e un’alleanza per la produzione di droni (6 miliardi di euro). Sul fronte economico, annunciata una tabella di marcia per rafforzare il mercato unico entro il 2028, liberalizzando servizi, energia e telecomunicazioni. In materia ambientale, confermata la riduzione del 90% delle emissioni al 2040, con il futuro dell’auto orientato all’elettrico, ma restano dubbi sui costi. L’industria automobilistica europea, riunita a Monaco, chiede più flessibilità normativa, appello sostenuto anche dal cancelliere tedesco Merz. Ne parliamo con Adriana Cerretelli, editorialista Sole 24 Ore Bruxelles.Macron nomina nuovo premier il giovane LecornuEmmanuel Macron ha nominato premier Sébastien Lecornu, 39 anni, ministro delle Forze Armate e suo fedelissimo, dopo le dimissioni di François Bayrou. Lecornu eredita un contesto complicato: una manovra da 43,8 miliardi, un voto di sfiducia e una maggioranza frammentata. Dovrà costruire una coalizione stabile, con LFI che continua a chiedere la destituzione di Macron. La nomina segna anche una rivincita politica del presidente, che aveva scelto Lecornu già a dicembre. Intanto, proteste in strada e oltre 100 arresti, soprattutto a Parigi. Il commento è di Marc Lazar, Presidente della School of Government dell'Università Luiss.Istat, boom prezzi alimentari: +30% rispetto al 2019 Secondo l’Istat, a luglio 2025 i prezzi degli alimentari in Italia sono saliti del 30,1% rispetto al 2019, meno della media UE (+39,2%). Germania e Spagna hanno registrato rincari maggiori, mentre la Francia un aumento più contenuto (+27,5%). L’aumento dei beni alimentari (88,5% del “carrello della spesa”) ha allargato il divario con l’inflazione generale, influenzata anche dai prezzi energetici: a agosto il differenziale ha raggiunto 1,9 punti percentuali. Interviene Massimo Baldini, docente di Scienza delle Finanze presso l' Università di Modena e Reggio Emilia.Novo Nordisk taglierà 9.000 posti di lavoro. Nel 2025 stime profitti riviste tre volte. Pesa la concorrenzaDopo aver perso il 60% in Borsa e 170 miliardi di euro di capitalizzazione, Novo Nordisk annuncia 9.000 tagli (11% della forza lavoro) per risparmiare 1,3 miliardi di dollari entro il 2026. Riviste al ribasso per la terza volta le stime di crescita dei profitti, ora previste tra il 4% e il 10% contro il 27% stimato a inizio anno. L’azienda punta a riorganizzarsi per concentrarsi su diabete e obesità, ma soffre la concorrenza di Eli Lilly, che domina il mercato Usa. Tentativi legali contro copie non autorizzate del semaglutide non hanno fermato la perdita di quote. Il nuovo Ceo Doustdar parla di decisioni difficili ma necessarie per il futuro. Il commento è affidato a Biagio Simonetta, Il Sole 24 Ore.

Nikki Glaser joins Jenna in Studio 1A as co-host for the day. She answers a rapid-fire round of questions on the latest in pop culture and reveals some hot takes. Also, Julianne Moore joins to discuss her continued love for acting, her latest Netflix show ‘Sirens,' and her partnership with Eli Lilly. Plus, Hoda is back to share the story of a remarkable New Orleans principal who is inspiring her students and many others. And, Chrissy Teigen stops by to raise awareness about an issue very personal to her.

We discuss the May 16 FDA approval of the first blood test to diagnose Alzheimer disease. This landmark approval marks a significant shift in how Alzheimer disease is identified, moving away from more traditional methods or invasive methods. Our guests, Howard Fillit, the Alzheimer's Drug Discovery Foundation, and Anthony “Nino” Sireci, MD, MSc, Eli Lilly and Company, help us understand this “huge accomplishment" and how it may be able to transform the diagnostic landscape from one of nihilism to one of hope and early intervention.

From pharmacist to Eli Lilly sales rep in just 5 weeks.In this episode, Francesco Russo shares how he went from burnout in retail pharmacy to landing a high-paying role in pharmaceutical sales thanks to strategy, networking, and a customized plan. His story proves that even highly educated professionals need more than degrees to stand out.Do you want to break into pharma or medical sales? Learn the strategies Francesco used inside this episode.

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

AI is revolutionizing pharmaceuticals, moving from a side tool to a core driver of many aspects of the industry. Eli Lilly is leading the way, appointing Thomas Fuchs as its first Chief AI Officer to integrate AI across its pipeline. A NASA and Mount Sinai veteran, Fuchs is turning Lilly's data into a competitive edge. He joins Inside the ICE House to share how Lilly is building the AI-powered medicine company of the future.

This week's Market Mondays is packed with high-level investing questions and timely market insights. We break down which five companies could thrive under a Trump administration, discuss whether Nvidia has a revenue concentration problem, and share advice for investors earning $50K–$100K per year on how to balance stocks, bonds, and real estate. We also dive into how to calculate intrinsic value—Ben Graham style, Warren Buffett style, or your own strategy—and what to actually do when your 5–10 year holding period is up.We also explore September 2025 market outlooks, Morgan Stanley's latest stock picks, and Alibaba's surprising surge after reports it may challenge Nvidia in the AI chip space. From fixed income products like MSTY and NVDY to the crypto markets hovering at key Fibonacci levels, we break down what's holding Bitcoin and ETH back, and how investors should be positioning in a historically tricky month. Plus, we play a round of “Don't Love, Marry, Kill” with Charter Communications, Hormel Foods, and Keurig Dr Pepper.Finally, we dig into the brewing legal storm around Novo Nordisk and Eli Lilly, facing over 2,000 lawsuits tied to Ozempic and similar drugs, with potential liability estimated in the billions. Is this the “death of Novo Nordisk,” or just another chapter in the evolving GLP-1 drug story? Tune in for sharp analysis, real strategies, and answers to the questions you've been asking all week.#MarketMondays #Investing #Stocks #Crypto #AI #Trump #Nvidia #Ozempic #WealthBuilding #FinancialLiteracyOur Sponsors:* Check out PNC Bank: https://www.pnc.com* Check out Square: https://square.com/go/eylSupport this podcast at — https://redcircle.com/marketmondays/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this episode, Scott Becker covers 16 business and market updates, including NVIDIA earnings, Eli Lilly's weight loss pill, EchoStar's deal with AT&T, and more.

President Trump looking to remove Fed Governor Lisa Cook after allegations of mortgage fraud. The battle brewing at the central bank, and how she's fighting back. Plus A major win in Eli Lilly's weight loss ambitions. The pill trial results pushing that drug towards approval, and what it means for the obesity drug wars. Fast Money Disclaimer 

Cramer says this pharmaceutical giant's stock can climb. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market's biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

Carl Quintanilla, Jim Cramer and David Faber engaged in a wide-ranging discussion about the White House taking its attacks on the Fed to an unprecedented level. President Trump said he fired Fed Governor Lisa Cook amid mortgage fraud allegations, but Cook responded by saying Trump has no authority to remove her and that she is not resigning. What might it all mean for Fed independence and the markets? Also in focus: What Commerce Secretary Lutnick told CNBC about the U.S. government potentially taking stakes in defense contractors, EchoStar soars on its $23 billion spectrum deal with AT&T, Eli Lilly obesity pill trial results, Nvidia earnings one day away.Squawk on the Street Disclaimer

President Trump saying he's firing Fed Governor Lisa Cook; Lisa Cook firing back that he doesn't have the authority – and she's not stepping down. Carl Quintanilla, David Faber, and Michael Santoli broke down the latest developments in the story, before talking potential fallout with Jefferies Strategist and Fed Chair contender David Zervos. Plus: the outlook for stocks amid the volatility – and better-than-expected consumer confidence data… Nuveen's Chief Investment Officer joined the team with her take on the action.  Also in focus: a number of market movers in early trading… Interactive Brokers shares gaining on news it's joining the S&P 500: Chairman & Founder Thomas Peterffy discussed where he sees growth ahead in the business – and broader markets. Eli Lilly also in the green on new obesity pill data: hear more on how to play shares with an analyst forecasting big gains ahead. Plus: a deep-dive on how AI is impacting a big part of the finance industry – excel spreadsheets. Squawk on the Street Disclaimer